Beese Fulmer Investment Management Inc. Boosts Eli Lilly Stake

Institutional investor increases holdings in pharmaceutical giant by nearly 50%

Mar. 11, 2026 at 7:34am

Got story updates? Submit your updates here. ›

Beese Fulmer Investment Management Inc., an institutional investor, increased its holdings in Eli Lilly and Company (NYSE:LLY) by 49.8% in the 3rd quarter, according to a recent SEC filing. The firm now owns 4,864 shares of the pharmaceutical company's stock, valued at $3.7 million.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for developing innovative drugs and therapies. Institutional investors closely monitor and adjust their positions in Lilly, as the company's performance and pipeline can significantly impact its stock price and shareholder returns.

The details

Beese Fulmer Investment Management Inc. added 1,616 shares to its Eli Lilly position during the 3rd quarter, bringing its total holdings to 4,864 shares. The firm's investment in Lilly is now valued at $3.7 million. Other hedge funds have also been active in trading Lilly's stock, with some increasing their positions and others reducing their stakes.

  • Beese Fulmer increased its Eli Lilly holdings in the 3rd quarter of 2026.

The players

Beese Fulmer Investment Management Inc.

An institutional investment firm that manages assets for clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

Eli Lilly's strong performance and promising drug pipeline continue to attract institutional investors like Beese Fulmer, who are betting on the company's long-term growth potential. The increased stake by Beese Fulmer reflects the firm's confidence in Lilly's ability to deliver shareholder value.